Drug development (and academic medicine): charting the course forward

Abstract

Drug development is both scientifically and economically driven. Past efforts to support the process have had great success, but increasing economic and regulatory pressures again threaten continued progress. The path from discovery to clinical use is in need of reevaluation with regard to substantive changes to reenergize the process. Such reevaluation includes clinical pharmacology input from all in our academia, industry, and regulatory sectors.